StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
July 26, 2024 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees |
---|---|---|
July 26, 2024 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors |
July 25, 2024 | Timely Disclosure Information | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors |
July 25, 2024 | Timely Disclosure Information | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees |
July 25, 2024 | Timely Disclosure Information | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator |
April 25, 2023 | NEWS Release |
---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.